Sino Biopharm is a leading Chinese pharmaceutical company continuing to invest in Oncology, Hepatology, Respiratoryand Surgery, exploring innovative therapies to improve the lives of patients. The company has strong manufacturingcapabilities and broad patient access across China. Sino Biopharm is committed to bring innovation to address unmethealthcare needs globally. The company was listed on the Hong Kong Stock Exchange in 2000, and was selected as acomponent of the Mscl Global Standard index in China in 2013; in 2018, it was selected as a constituent stock of HancSeng index; The company has been listed in the "Top 50 Global Pharmaceutical Enterprises" published by theauthoritative American magazine Pharmaceutical Manager for four consecutive years, and has been rated as the "Top

50 Best Companies in Asia Pacific" by Forbes (Asia) for three consecutive years.